Granted Patent
B2
US 12,296,002 · App. 17/351,363 · Granted May 13, 2025
Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Inventors:
Tsun-Yung Kuo (I-Lan County, TW); Charles Chen (Taipei, TW); Chung-Chin Wu (I-Lan County, TW); Yi-Jiun Lin (Taipei, TW); Meei-Yun Lin (Taipei, TW); Yu-Chi Wu (Taipei, TW); John Darren Campbell (Emeryville, CA); Robert S. Janssen (Emeryville, CA); David Novack (Emeryville, CA); Robert Coffman (Emeryville, CA); Paula Traquina (Emeryville, CA)
A61K39/215A61P31/14C07K14/005C07K14/165C07K14/245A61K2039/54A61K2039/545A61K2039/55505A61K2039/55561A61K2039/575C07K2319/33C12N2770/20022C12N2770/20034C12N2770/20071C12N2795/10022C12N2795/10034C12N2795/10071
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
Claims (14)
1. An immunogenic composition against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising an antigenic recombinant protein and an adjuvant consisting of aluminum hydroxide and an unmethylated cytosine-phosphate-guanosine (CpG) motif consisting of a synthetic oligodeoxynucleotide (ODN) of SEQ ID NO: 8, wherein the antigenic recombinant protein substantially consists of residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a “GSAS” substitution at residues 682-685 and a C-terminal T4 fibritin trimerization domain consisting of an amino acid sequence of SEQ ID NO: 2.
2. The immunogenic composition of claim 1 , wherein the residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a “GSAS” substitution at residues 682-685 comprise an amino acid sequence of SEQ ID NO: 1 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 1.
3. The immunogenic composition of claim 1 , wherein the antigenic recombinant protein comprises an amino acid sequence of SEQ ID NO: 5 or 6 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 5 or 6.
4. The immunogenic composition of claim 1 , wherein a 0.5 ml dose of the immunogenic composition comprises from about 250 to about 500 μg Al 3+ , or about 375 μg Al 3+ .
5. The immunogenic composition of claim 1 , wherein a 0.5 ml dose of the immunogenic composition comprises from about 750 to about 3000 μg of the synthetic oligodeoxynucleotide, or wherein the immunogenic composition comprises about 750 μg, about 1500 μg, or about 3000 μg of the synthetic oligodeoxynucleotide.
6. A method for eliciting an immune response against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof, comprising administering to the subject an effective amount of an immunogenic composition comprising an antigenic recombinant protein and an adjuvant consisting of aluminum hydroxide and an unmethylated cytosine-phosphate-guanosine (CpG) motif consisting of a synthetic oligodeoxynucleotide (ODN) of SEQ ID NO: 8, wherein the antigenic recombinant protein substantially consists of residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a “GSAS” substitution at residues 682-685 and a C-terminal T4 fibritin trimerization domain consisting of an amino acid sequence of SEQ ID NO: 2.
7. The method of claim 6 , wherein the residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a “GSAS” substitution at residues 682-685 comprise an amino acid sequence of SEQ ID NO: 1 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 1.
8. The method of claim 6 , wherein the antigenic recombinant protein comprises an amino acid sequence of SEQ ID NO: 5 or 6 or the amino acid sequence at least 90%, 95% 96%, 97%, 98%, or 99% to SEQ ID NO: 5 or 6.
9. The method of claim 6 , wherein a 0.5 ml dose of the immunogenic composition comprises from about 250 to about 500 μg Al 3+ , or about 375 μg Al 3+ .
10. The method of claim 6 , wherein a 0.5 ml dose of the immunogenic composition comprises from about 750 to about 3000 μg of the synthetic oligodeoxynucleotide, or wherein the immunogenic composition comprises about 750 μg, about 1500 μg, or about 3000 μg of the synthetic oligodeoxynucleotide.
11. The method of claim 6 , wherein the immune response comprises production of neutralizing antibodies against SARS-CoV-2 and Th1-skewed immune response.
12. The method of claim 6 , wherein the immunogenic composition is administered by intramuscular injection.
13. A method for protecting a subject in need thereof from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or preventing the subject in need thereof from contracting COVID-19 disease, comprising administering to the subject an effective amount of the immunogenic composition of claim 1 .
14. The method of claim 13 , wherein the immunogenic composition is administered by intramuscular injection.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 7, 2023
From: COFFMAN, ROBERT; TRAQUINA, PAULA
To: DYNAVAX TECHNOLOGIES CORPORATION
Reel/Frame 062908/0693 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 11, 2021
From: KUO, TSUN-YUNG; CHEN, CHARLES; WU, CHUNG-CHIN; LIN, YI-JIUN; LIN, MEEI-YUN; WU, YU-CHI; CAMPBELL, JOHN DARREN; JANSSEN, ROBERT S.; NOVACK, DAVID
To: MEDIGEN VACCINE BIOLOGICS CORPORATION; DYNAVAX TECHNOLOGIES CORPORATION
Reel/Frame 057750/0037 →
Continuity (4)
Continuation
PCTUS2021020277
· Mar 1, 2021
Provisional Application
63040696
· Jun 18, 2020
Provisional Application
62983737
· Mar 1, 2020
References Cited (179)
US 6309650B1
· Kim et al.
· 2001
[cited by applicant]
US 6589940B1
· Raz et al.
· 2003
[cited by applicant]
US 20060257852A1
· Rappuoli et al.
· 2006
[cited by applicant]
US 20070116716A1
· Shen et al.
· 2007
[cited by applicant]
US 20080305120A1
· Messmer
· 2008
[cited by examiner]
US 20090017069A1
· Akeefe et al.
· 2009
[cited by applicant]
US 20090104229A1
· Voss
· 2009
[cited by applicant]
US 20120121630A1
· Bryan
· 2012
[cited by examiner]
US 20190134190A1
· Rittner et al.
· 2019
[cited by applicant]
US 20210260181A1
· Georges et al.
· 2021
[cited by applicant]
US 20230092650A1
· Campbell et al.
· 2023
[cited by applicant]
US 20230110516A1
· Campbell et al.
· 2023
[cited by applicant]
US 20230218740A1
· Campbell et al.
· 2023
[cited by applicant]
CN 1827936A
· 2006
[cited by applicant]
CN 101240271A
· 2008
[cited by applicant]
CN 102068692A
· 2011
[cited by applicant]
CN 111218458A
· 2020
[cited by applicant]
EP 2484378A1
· 2012
[cited by applicant]
WO 200020039A1
· 2000
[cited by applicant]
WO 200062802A2
· 2000
[cited by applicant]
WO 200062802A3
· 2001
[cited by applicant]
WO 200100232A2
· 2001
[cited by applicant]
WO 200100232A3
· 2001
[cited by applicant]
WO 2003011334A1
· 2003
[cited by applicant]
WO 2004092360A2
· 2004
[cited by applicant]
WO 2004094614A2
· 2004
[cited by applicant]
WO 2004092360A3
· 2005
[cited by applicant]
WO 2005111238A2
· 2005
[cited by applicant]
WO 2005111238A3
· 2006
[cited by applicant]
WO 2004094614A3
· 2006
[cited by applicant]
WO 2007122392A1
· 2007
[cited by applicant]
WO 2013083726A1
· 2013
[cited by applicant]
WO 2014153087A1
· 2014
[cited by applicant]
WO 2016203025A1
· 2016
[cited by applicant]
WO 2017109223A1
· 2017
[cited by applicant]
WO 2017109225A1
· 2017
[cited by applicant]
WO 2018081318A1
· 2018
[cited by applicant]
WO 2018147265A1
· 2018
[cited by applicant]
WO 2018200645A1
· 2018
[cited by applicant]
WO 2019057793A1
· 2018
[cited by applicant]
WO 2021048221A1
· 2021
[cited by applicant]
WO 2021176434A1
· 2021
[cited by applicant]
WO 2021178318A1
· 2021
[cited by applicant]
WO 2021178321A1
· 2021
[cited by applicant]
WO WO2021178661
· 2021
[cited by examiner]
WO 2021178877A1
· 2021
[cited by applicant]
WO 2021204825A2
· 2021
[cited by applicant]
WO 2021254473A1
· 2021
[cited by applicant]
SEQ 1 alignment with Geneseq db access BJY36088 Mar. 25, 2020.
[cited by examiner]
Alignment of SEQ 2 with UniProt db access M1E1E4_9HIV1 2014.
[cited by examiner]
Alignment of SEQ ID No. 5 with Geneseq db access BKD68505 by Henderson Apr. 14, 2020.
[cited by examiner]
Abdullah, S.F. et al. (2020, e-pub. Jun. 30, 2020). “SARS-CoV-2: A Piece of Bad News,” Medeniyet Med. J. 35(2):151-160.
[cited by applicant]
Afrough, B. et al. (May 2019). “Emerging Viruses and Current Strategies For Vaccine Intervention,” Clin Exp. Immunol. 196(2):157-166.
[cited by applicant]
Agrawal, A.S. et al. (2016, e-pub. Jun. 7, 2016). “Immunization with Inactivated Middle East Respiratory Syndrome Coronavirus Vaccine Leads to Lung Immunopathology on Challenge with Live Virus,” Human Vaccines & Immunot…
[cited by applicant]
Ahmed, S.F. et al. (2020, e-pub. Feb. 25, 2020). “Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies,” Viruses 12(3):254, 15 pages.
[cited by applicant]
Amanat, F. et al. (Jul. 16, 2020). “A Serological Assay To Detect SARS-CoV-2 Seroconversion In Humans,” MedRxiv, Jan. 26, 2012.
[cited by applicant]
Anonymous (2021). “What's in Vaccines?,” The Center for Disease Control and Prevention, 2 pages.
[cited by applicant]
Anonymous (Jan. 30, 2020). “Novel Coronavirus (2019-nCOV), Situation Report 10,” World Health Organization, 7 pages.
[cited by applicant]
Anonymous (Jun. 24, 2022). “Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001,” Valneva Press Release, 4 pages.
[cited by applicant]
Arunachalam, P.S. et al. (2021, e-pub. Apr. 19, 2021). “Adjuvanting a Subunit COVID-19 Vaccine To Induce Protective Immunity,” Nature 594:253-258, 27 pages.
[cited by applicant]
Bao, L. et al. (Mar. 4, 2020), “Reinfection Could Not Occur In SARS-Co V-2 Infected Rhesus Macaques,” BioRxiv, 20 pages.
[cited by applicant]
Bao, M. et al. (2006, e-pub. Nov. 17, 2005). “Anti-SARS-CoV Immunity Induced by a Novel CpG Oligodeoxynucleotide,” Clinical Immunology 118:180-187.
[cited by applicant]
Berger, A. (Aug. 12, 2000). Th1 and Th2 Responses: What Are They? BMJ. 321(7258):424, 1 page.
[cited by applicant]
Bode, C. et al. (Apr. 2011). “CpG DNA as a Vaccine Adjuvant,” Expert Rev Vaccines 10(4):499-511, author manuscript, 22 pages.
[cited by applicant]
Braun, R.P. et al. (Sep. 15, 1988). “Immunogenic Duplex Nucleic Acids Are Nuclease Resistant,” J Immunol. 141(6):2084-2089.
[cited by applicant]
Callaway, E. (Apr. 2020). “The Race for Coronavirus Vaccines: A Graphical Guide,” Nature 580(7805):576-577.
[cited by applicant]
Campbell, J.D. (2017). “Chapter 2: Development of The CpG Adjuvant 1018: A Case Study,” Methods Mol Biol. 1494:15-27.
[cited by applicant]
Capobianchi, M.R. et al. (2020, e-pub. Mar. 27, 2020). “Molecular Characterization of SARS-CoV-2 From The First Case of COVID-19 in Italy,” Clin. Microbial Infect. 26(7):954-956.
[cited by applicant]
Chan, J.F.-W. et al. (2020, e-pub. Jan. 28, 2020). “Genomic Characterization of the 2019 Novel Human-Pathogenic Coronavirus Isolated From a Patient With Atypical Pneumonia After Visiting Wuhan,” Emerging Microbes & Infe…
[cited by applicant]
Chen, Y. et al. (2020, e-pub. Feb. 17, 2020). “Structure Analysis of the Receptor Binding of 2019-nCoV,” Biochemical and Biophysical Research Communications 525:135-140.
[cited by applicant]
Chuang, T.-H. et al. (Mar. 2002). “Toll-Like Receptor 9 Mediates CpG-DNA Signaling,” J Leukoc Biol. 71(3):538-544.
[cited by applicant]
Coffman, R.L. et al. (Oct. 29, 2010) “Vaccine Adjuvants: Putting Innate Immunity to Work,” Immunity 33(4):492-503, author manuscript, 21 pages.
[cited by applicant]
Darnell, M.E.R. et al. (2004, e-pub. Aug. 3, 2004). “Inactivation of The Coronavirus That Induces Severe Acute Respiratory Syndrome, SARS-CoV,” J. Virol. Methods 121(1):85-91.
[cited by applicant]
Deng, Y. et al. (2018, e-pub. Apr. 4, 2018). “Enhanced Protection in Mice Induced By Immunization With Inactivated Whole Viruses Compare to Spike Protein of Middle East Respiratory Syndrome Coronavirus,” Emerging Microb…
[cited by applicant]
Devereux, J. et al. (1984). “A Comprehensive Set Of Sequence Analysis Programs For The VAX,” Nucleic Acids Research 12(1):387-395.
[cited by applicant]
Draper, S.J. et al. (Jul. 11, 2018). “Malaria Vaccines: Recent Advances and New Horizons,” Cell Host Microbe 24(1):43-56.
[cited by applicant]
Du, L. et al. (2009, e-pub. Feb. 9, 2009). “The Spike Protein of SARS-CoV-a Target For Vaccine and Therapeutic Development,” Nature Reviews Microbiology, 7:226-236.
[cited by applicant]
Enjuanes, L. et al. (2016, e-pub. Aug. 30, 2016). “Molecular Basis of Coronavirus Virulence and Vaccine Development,” Adv. Virus Res. 96:245-286, 31 pages.
[cited by applicant]
Excler, J.-L. et al. (2021, e-pub. Apr. 12, 2021). “Vaccine Development For Emerging Infectious Diseases,” Nat Med. 27(4):591-600.
[cited by applicant]
Hyer, R. et al. (2019, e-pub. Aug. 17, 2019). “Immunogenicity and Safety of a 2-Dose Hepatitis B Vaccine, HBsAg/CpG 1018, in Persons with Diabetes Mellitus Ages 60-70 Years,” Vaccine 37(39):5854-5861.
[cited by applicant]
Ferguson, N.M. et al. (Mar. 16, 2020). “Report 9: Impact of Non-Pharmaceutical Interventions (NPIs) To Reduce COVID-19 Mortality and Healthcare Demand,” Imperial College London, 20 pages.
[cited by applicant]
Francica, J.R. et al. (Nov. 28, 2017). “Innate Transcriptional Effects By Adjuvants On The Magnitude, Quality and Durability of HIV Envelope Responses In NHPs,” Blood Adv. 1(25):2329-2342.
[cited by applicant]
Frieman, M. et al. (2012, e-pub. Nov. 9, 2011). “Molecular Determinants Of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence In Young and Aged Mouse Models Of Human Disease,” J. Virol. 86(2):884-8…
[cited by applicant]
Gao, Q. et al. (2020, e-pub. May 6, 2020). “Development of an Inactivated Vaccine Candidate For SARS-CoV-2,” Science 369(6499):77-81, 5 pages.
[cited by applicant]
GENBANK Submission; NIH/NCBI, Accession No. MN908947.3. Wu et al., Mar. 18, 2020, 11 pages.
[cited by applicant]
GENBANK Submission; NIH/NCBI, Accession No. MT066156.1 Capobianchi et al., Apr. 13, 2020, 11 pages.
[cited by applicant]
Glass, W.G. et al. (Sep. 15, 2004). “Mechanisms of Host Defense Following Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) Pulmonary Infection of Mice,” J. Immunol. 173(6):4030-4039.
[cited by applicant]
Graham, B.S. et al. (2018, e-pub. Dec. 14, 2017). “Emerging Viral Diseases From a Vaccinology Perspective: Preparing For The Next Pandemic,” Nat Immunol. 19(1):20-28.
[cited by applicant]
Graham, R.L. et al. (2013, e-pub. Nov. 11, 2013). “A Decade After SARS: Strategies For Controlling Emerging Coronaviruses,” Nature Reviews Microbiology, 11:836-848.
[cited by applicant]
Gupta, D. et al. (2021, e-pub. Apr. 23, 2021). “Inactivation of SARS-COV-2 by β-propiolactone Causes Aggregation of Viral Particles and Loss of Antigenic Potential,” 305:198555, 9 pages.
[cited by applicant]
Han, Q. et al. (2020, e-pub. Feb. 11, 2020). “Coronavirus 2019-nCoV: A Brief Perspective From The Front Line,” J Infect. 80(4):373-377.
[cited by applicant]
He, Y. et al. (2004, e-pub. Oct. 28, 2004). “Inactivated SARS-CoV Vaccine Elicits High Titers of Spike Protein-Specific Antibodies That Block Receptor Binding and Virus Entry,” Biochem. Biophys. Res. Commun. 325(2):445-…
[cited by applicant]
Henikoff, S. et al. (Nov. 15, 1992). “Amino Acid Substitution Matrices From Protein Blocks,” Proc. Nat'l Acad. Sci. USA 89:10915-10919.
[cited by applicant]
Herrera-Rodriguez, J. et al. (2019, e-pub. Feb. 11, 2019). “Inactivated or Damages? Comparing the Effect of Inactivation Methods on Influenza Virions to Optimize Vaccines Production,” Vaccine 37(12):1630-1637.
[cited by applicant]
Hogan, R.J. et al. (Oct. 2004). “Resolution of Primary Severe Acute Respiratory Syndrome-Associated Coronavirus Infection Requires Stat1,” J. Virol. 78(20):11416-11421.
[cited by applicant]
Hombach, J. et al. (2005, e-pub. Jul. 18, 2005). “Report on a WHO Consultation On Immunological Endpoints For Evaluation of New Japanese Encephalitis Vaccines, WHO, Geneva, Sep. 2-3, 2004,” Vaccine. 23(45):5205-5211.
[cited by applicant]
Hotez, P.J. et al. (Jul. 2020). “COVID-19 Vaccines: Neutralizing Antibodies and The Alum Advantage,” Nat. Rev. Immunol. 20(7):399-400.
[cited by applicant]
Huh, K. et al. (Mar. 2020). “Emergent Strategies for the Next Phase of COVID-19,” Infect Chemother. 52(1):105-109.
[cited by applicant]
Ioannou, X.P. et al. (Nov. 22, 2002). “CpG-Containing Oligodeoxynucleotides, In Combination With Conventional Adjuvants, Enhance The Magnitude and Change The Bias Of The Immune Responses To a Herpesvirus Glycoprotein,” …
[cited by applicant]
Jureka, A.S. et al. (Jun. 6, 2020). “Propagation, Inactivation, and Safety Testion of SARS-CoV-2,” Viruses 12(6):622, 13 pages.
[cited by applicant]
Khan, J. et al. (Apr. 2020). “We've Never Made a Successful Vaccine For a Coronavirus Before. This Is Why It's So Difficult,” ABC Health and Wellbeing, retrieved from the Internet https://www.abc.net.au/news/health/2020…
[cited by applicant]
Wang, S.-F. et al. (2014, e-pub. Jul. 26, 2014). “Antibody-Dependent SARS Coronavirus Infection Is Mediated By Antibodies Against Spike Proteins,” Biochem. Biophys. Res. Commun. 451(2):208-214.
[cited by applicant]
Wang, Z.-B. et al. (Mar. 13, 2020). “Better Adjuvants For Better Vaccines: Progress In Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery,” Vaccines (Basel). 8(1):128, 20 pages.
[cited by applicant]
Wrapp, D. et al. (2020, e-pub. Feb. 19, 2020). “Cryo-EM Structure of the 2019-nCoV Spiked in the Prefusion Conformation,” Science 367:1260-1263.
[cited by applicant]
Wu, F. et al. (2020, e-pub Feb. 3, 2020). “A New Coronavirus Associated with Human Respiratory Disease in China,” Nature 579(7798):265-269, 20 pages.
[cited by applicant]
Wu, Z. et al. (Apr. 7, 2020). “Characteristics of and Important Lessons From The Coronavirus Disease 2019 (COVID-19) Outbreak In China: Summary Of a Report of 72 314 Cases From The Chinese Center For Disease Control and…
[cited by applicant]
Zakhartchouk, A.N. et al. (2007, e-pub. Aug. 2, 2008). “Immunogenicity of a Receptor-Binding Domain of SARS Coronavirus Spike Protein in Mice: Implications for a Subunit Vaccine,” Vaccine 25:136-143.
[cited by applicant]
Zeng, W. et al. (2020, e-pub. Apr. 30, 2020). “Biochemical Characterization of SARS-CoV-2 Nucleocapsid Protein,” Biochem. Biophys. Res. Commun. 527(3):618-623.
[cited by applicant]
Zhang, B.-Z. et al. (2020, e-pub. Jul. 1, 2020). “Mining of Epitopes On Spike Protein of SARS-CoV-2 From COVID-19 Patients,” Cell Res. 30(8):702-704.
[cited by applicant]
Zhang, J. et al. (2020). “Progress and Prospects on Vaccine Development Against SARS-CoV-2,” Vaccines 8:153, 12 pages.
[cited by applicant]
Zhao, K. et al. (2011, e-pub. Jul. 13, 2011). “The Immune Responses of HLA-A*0201 Restricted SARS-CoV S Peptide-Specific CD8+ T Cells are Augmented in Varying Degrees by CpGODN, Polyl:C and R848,” Vaccine 29:6670-6678.
[cited by applicant]
Zhou, P. et al. (2020, e-pub. Feb. 3, 2020). “A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin,” Nature, 579:270-273, 20 pages.
[cited by applicant]
Zhu, N. et al. (2020, e-pub. Jan. 24, 2020). “A Novel Coronavirus From Patients With Pneumonia In China 2019,” N Engl. J. Med. 382(8):727-733.
[cited by applicant]
Weissman, D. et al. (Jan. 13, 2021). “D614G Spike Mutation Increase SARS CoV-2 Susceptibility to Neutralization,” Cell Host of Microb. 29:23-31.
[cited by applicant]
Xiong, X. et al. (Oct. 1, 2020). “A Thermostable, Closed SARS-CoV-2 Spike Protein Trimer,” Nat. Struct. Mol. Biol. 27(10):934-941, 27 pages.
[cited by applicant]
Kobinger, G.P. et al. (2007, e-pub. May 7, 2007). “Adenovirus-Based Vaccine Prevents Pneumonia In Ferrets Challenged With The SARS Coronavirus and Stimulates Robust Immune Responses In Macaques,” Vaccine. 25(28):5220-52…
[cited by applicant]
Kulkarni, R. (Nov. 2019). “Antibody-Dependent Enhancement of Viral Infections,” Dynamics of Immune Activation in Viral Diseases 5:9-41.
[cited by applicant]
Kuo, T.-Y. et al. (2020). “Development of CpG-Adjuvanted Stable Prefusion SARS-CoV-2 Spike Antigen As a Subunit Vaccine Against COVID-19,” Scientific Reports, 10:20085, 10 pages.
[cited by applicant]
Lambert, P.-H. et al. (2020, e-pub. May 25, 2020). “Consensus Summary Report For CEPI/BC Mar. 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement With COVID-19 Vaccines,” Vaccine 38(31):4783-4791, 10 pages.
[cited by applicant]
Lan J. et al. (2014, e-pub. Nov. 18, 2014). “Tailoring Subunit Vaccine Immunity With Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain As an Antig…
[cited by applicant]
Latimer, L.J.P. et al. (Oct. 1995). “Specificity of Monoclonal Antibodies Produced Against Phosphorothioate and Ribo Modified DNAs,” Mol. Immunol. 32(14/15):1057-1064.
[cited by applicant]
Lazarus, R. et al. (2022, e-pub. Sep. 5, 2022). “Immunogenicity and Safety of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001) Compared with the Adenoviral Vector Vaccine ChAdOx1-S in Adults in the UK (COVCOMPARE):…
[cited by applicant]
Letko, M. et al. (2020, e-pub. Feb. 24, 2020). “Functional Assessment of Cell Entry and Receptor Usage For SARS-CoV-2 and Other Lineage B Betacoronaviruses,” Nature Microbiology, 5(4):562-569.
[cited by applicant]
Li, J.-Y. et al. (2020, e-pub. Feb. 2020). “The Epidemic of 2019-Novel-Coronavirus (2019-nCoV) Pneumonia and Insights For Emerging Infectious Diseases In The Future,” Microbes Infect. 22(2):80-85.
[cited by applicant]
Liang, J.G. et al. (2021, e-pub. Mar. 1, 2021). “S-Trimer, a COVID-19 Subunit Vaccine Candidate, Induces Protective Immunity In Nonhuman Primates,” Nat Commun. 12(1):1346, 12 pages.
[cited by applicant]
Lien, C.-E. et al. (2021, e-pub Apr. 22, 2021). CpG-Adjuvanted Stable Prefusion SARS-CoV-2 Spike Protein Protected Hamsters From SARS-CoV-2 Challenge, Scientific Reports, 11: 8761. 7 pages.
[cited by applicant]
Lin, J.-T. et al. (2007). “Safety and Immunogenicity From a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Corona Virus Vaccine,” Antivir. Ther. 12(7):1107-1113.
[cited by applicant]
Luo, F. et al. (2018, e-pub. Mar. 14, 2018). “Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection In Rhesus Macaques Immunized With an Inactivated SARS-CoV Vaccine,” Virol Sin. 33(2):201-204.
[cited by applicant]
Maisonnasse, P. et al. (2020, e-pub. Jul. 22, 2020). “Hydroxychloroquine Use Against SARS-CoV-2 Infection In Non-Human Primates,” Nature 585(7826):584-587 and Supplemental Information, 18 pages.
[cited by applicant]
Needleman, S. B. et al. (Mar. 1970). “A General Method Applicable to the Search for Similarities in the Amino Acid sequence of Two Proteins,” J. Mol. Biol. 48:443-453.
[cited by applicant]
Ng, M.-L. et al. (Dec. 2003). “Proliferative Growth of SARS Coronavirus In Vero E6 Cells,” J. Gen. Virol. 84(12):3291-3303.
[cited by applicant]
Ou, X. et al. (Mar. 27, 2020). “Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity With SARS-CoV,” Nat. Commun. 11(1):1620.
[cited by applicant]
Pearson, W.R. et al. (Apr. 1988). “Improved Tools For Biological Sequence Comparison,” Proc. Natl. Acad. Sci. USA 85(8):2444-2448.
[cited by applicant]
Petrovsky, N. (Dec. 31, 2016). “SARS Coronavirus Infections of the Lower Respiratory Tract and Their Prevention,” Chapter 3—The Microbiology of Respiratory System Infections, pp. 45-53.
[cited by applicant]
Pramanick, S. et al. (Mar. 2013). “Excipient Selection In Parenteral Formulation Development,” Pharma Times 45(3):65-77.
[cited by applicant]
Rabaan, A.A. et al. (Apr. 7, 2020). “SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines To Counter This Emerging Pandemic,” 19:40, 37 pages.
[cited by applicant]
Ragan, I.K. et al. (2021, e-pub. Apr. 1, 2021). “A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model,” Vaccines, 9:340, 24 …
[cited by applicant]
Rauch, S. et al. (2018, e-pub. Sep. 19, 2018). “New Vaccine Technologies To Combat Outbreak Situations,” Front. Immunol. 9:1963, 38 pages.
[cited by applicant]
Richmond, P. et al. (2021, e-pub. Jan. 29, 2021). “Safety and Immunogenicity of S-Trimer (SCB-2019), A Protein Subunit Vaccine Candidate For COVID-19 In Healthy Adults: A Phase 1, Randomised, Double-Blind, Placebo-Contr…
[cited by applicant]
Roberts, A. et al. (2008, e-pub. May 11, 2007). “Animal Models and Vaccines For SARS-CoV Infection,” Virus Res. 133(1):20-32.
[cited by applicant]
Roberts, A. et al. (May 2005). “Aged BALB/c Mice as a Model For Increased Severity Of Severe Acute Respiratory Syndrome In Elderly Humans,” J. Virol. 79(9):5833-5838.
[cited by applicant]
Sah, R. et al. (Mar. 12, 2020). “Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated In Nepal,” Microbiol. Resour. Announc. 9(11):e00169-20, 3 pages.
[cited by applicant]
Schlegl, R. et al. (2015, e-pub. Jun. 19, 2015). “Influence of Elemental Impurities In Aluminum Hydroxide Adjuvant on The Stability of Inactivated Japanese Encephalitis Vaccine, IXIARO®,” Vaccine. 33(44):5989-5996.
[cited by applicant]
See, R.H. et al. (Sep. 2008). “Severe Acute Respiratory Syndrome Vaccine Efficacy In Ferrets: Whole Killed Virus and Adenovirus-Vectored Vaccines,” J Gen Virol. 89(Pt 9):2136-2146.
[cited by applicant]
Sekimukai, H. et al. (2020, e-pub. Nov. 2019). “Gold Nanoparticle-Adjuvanted S Protein Induces a Strong Antigen-Specific IgG Response Against Severe Acute Respiratory Syndrome-Related Coronavirus Infection, But Fails To…
[cited by applicant]
Shah, R.R. et al. (2017). “Chapter 1: Overview of Vaccine Adjuvants: Introduction, History, and current Status,” Methods Mol. Biol. 1494:1-13.
[cited by applicant]
Shang, J. et al. (2020, e-pub. Mar. 30, 2020). “Structural Basis of Receptor Recognition By SARS-CoV-2,” Nature. 581(7807):221-224, 18 pages.
[cited by applicant]
Shang, W. et al. (Mar. 6, 2020). “The Outbreak of SARS-CoV-2 Pneumonia Calls For Viral Vaccines,” NPJ Vaccines 5(1):18, 3 pages.
[cited by applicant]
Shanmugaraj, B. et al. (Feb. 22, 2020). “Emergence of Novel Coronavirus 2019-nCoV: Need For Rapid Vaccine and Biologics Development,” Pathogens 9(2):148, 10 pages.
[cited by applicant]
She, Y.-M. et al. (Dec. 2013). “Surface Modifications of Influenza Proteins Upon Virus Inactivation By β-propiolactone,” Proteomics 13(23-24):3537-3547.
[cited by applicant]
Shi, Y. et al. (2020, e-pub. Mar. 23, 2020). “COVID-19 Infection: The Perspectives On Immune Responses,” Cell Death Differ. 27(5):1451-1454.
[cited by applicant]
Spruth, M. et al. (2006, e-pub. Aug. 26, 2005). “A Double-Inactivated Whole Virus Candidate SARS Coronavirus Vaccine Stimulates Neutralising and Protective Antibody Responses,” Vaccine 24(5):652-661.
[cited by applicant]
Srivastava, A.K. et al. (Aug. 14, 2001). “A Purified Inactivated Japanese Encephalitis Virus Vaccine Made In Vero Cells,” Vaccine 19(31):4557-4565.
[cited by applicant]
Subbarao, K. et al. (Apr. 2004). “Prior Infection and Passive Transfer Of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Corona Virus In The Respiratory Tract Of Mice,” J. Virol. 78(7):35…
[cited by applicant]
Szurgot, I. et al. (Feb. 4, 2021). “DNA-Launched RNA Replicon Vaccines Induce Potent Anti-SARS-CoV-2 Immune Responses In Mice,” Sci. Rep. 11(1):3125, 13 pages.
[cited by applicant]
Tetro, J.A. (2020, e-pub. Feb. 22, 2020). Is COVID-19 Receiving ADE From Other Coronaviruses? Microbes Infect. 22(2):72-73.
[cited by applicant]
Thomas, L.J. et al. (2009, e-pub. Feb. 1, 2009). “Co-Administration of a CpG Adjuvant (VaxImmune, CPG 7909) With CETP vaccines Increased Immunogenicity In Rabbits and Mice,” Hum Vaccin. 5(2):79-84.
[cited by applicant]
Tian, X. et al. (2020, e-pub. Feb. 17, 2020). “Potent Binding of 2019 Novel Coronavirus Spike Protein By a SARS Coronavirus-Specific Human Monoclonal Antibody,” Emerg. Microbes Infect. 9(1):382-385.
[cited by applicant]
Tian, Y. et al. (Apr. 28, 2017). “The Novel Complex Combination of Alum, CpG ODN and HH2 As Adjuvant In Cancer Vaccine Effectively Suppresses Tumor Growth in vivo,” Oncotarget. 8(28):45951-45964.
[cited by applicant]
Tseng, C.-T. et al. (2012, e-pub. Apr. 20, 2012). “Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus,” PloS ONE, 7(4):e35421, 13 pages.
[cited by applicant]
Tseng, C.-T.K. et al. (2007, e-pub. Nov. 15, 2006). “Severe Acute Respiratory Syndrome Coronavirus Infection of Mice Transgenic For The Human Angiotensin-Converting Enzyme 2 Virus Receptor,” J Virol. 81(3):1162-1173.
[cited by applicant]
Uittenbogaard, J.P. et al. (2011, e-pub. Aug. 25, 2011). “Reactions of Beta-Propiolactone With Nucleobase Analogues, Nucleosides, and Peptides: Implications For The Inactivation of Viruses,” J. Biol. Chem. 286(42):36198…
[cited by applicant]
Walls, A. C. et al. (Apr. 16, 2020). “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein,” Cell 180(2):281-292, 38 pages.
[cited by applicant]
Wan, Y. et al. (2020, e-pub. Feb. 14, 2020). “Molecular Mechanism For Antibody-Dependent Enhancement of Coronavirus Entry,” J. Virol. 94(5):e02015-19, 15 pages.
[cited by applicant]
Wang, B. et al. (2020). “The Potential for Antibody-Dependent Enhancement of SARS-CoV-2 Infection: Transnational Implications for Vaccine Development,” Journal of Clinical and Translational Science 5:e2, 4 pages.
[cited by applicant]
Jie Li, Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates, Viral Immunology, Apr. 2013, pp. 126-132, v.26, No. 2, Mary Ann Liebert, In…
[cited by applicant]
Jesper Pallesen, Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen, PNAS, Aug. 14, 2017, pp. E7348-E7357, v.114, No. 35, National Academy of Sciences, Washington, D.C., USA.
[cited by applicant]
Shuting Shi, Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity, Vaccine, May 27, 2019, pp. 3167-3178, v.37, issue 24, Elsevier, Amsterdam, Netherlands.
[cited by applicant]
Daniel Wrapp, Supplementary Materials for Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, Feb. 19, 2020, pp. 1260-1263, v.367, No. 6483, American Association for the Advancement of Scien…
[cited by applicant]